BETA 2 GLYCOPROTEIN 1 IGM

The Beta 2 Glycoprotein 1 (β2GP1) IgM Antibody Test is a specialized blood test that detects Immunoglobulin M (IgM) autoantibodies directed against Beta 2 Glycoprotein 1 (β2GP1), a plasma protein that plays an important role in regulating blood clotting. This test is commonly used in the evaluation of Antiphospholipid Syndrome (APS), an autoimmune disorder associated with abnormal blood clot formation and pregnancy-related complications.

In Antiphospholipid Syndrome, the immune system mistakenly produces antibodies against phospholipid-binding proteins such as Beta 2 Glycoprotein 1. These antibodies interfere with the normal clotting process, increasing the risk of deep vein thrombosis (DVT), pulmonary embolism, stroke, heart attack, and recurrent pregnancy loss.

The Beta 2 Glycoprotein 1 IgM Antibody Test is one of the internationally recognized laboratory tests used in the diagnosis of APS. It is typically performed together with Beta 2 Glycoprotein 1 IgG, Anticardiolipin (IgG and IgM) antibodies, and Lupus Anticoagulant testing to provide a comprehensive evaluation of autoimmune clotting disorders.

Early detection of β2GP1 IgM antibodies helps physicians identify patients at risk of thrombotic events and pregnancy complications, allowing timely treatment with anticoagulants or other appropriate therapies.

Benefits of the Test

• Detects Beta 2 Glycoprotein 1 IgM autoantibodies
• Supports diagnosis of Antiphospholipid Syndrome (APS)
• Helps evaluate autoimmune clotting disorders
• Assists in investigating unexplained thrombosis
• Supports assessment of recurrent pregnancy loss
• Complements other antiphospholipid antibody tests
• Requires only a peripheral blood sample

Why Doctors Recommend This Test

Doctors may recommend this test for individuals with:

• Deep vein thrombosis (DVT)
• Pulmonary embolism
• Stroke or transient ischemic attack (TIA)
• Recurrent miscarriages
• Stillbirth or fetal loss
• Severe pre-eclampsia
• Unexplained blood clotting disorders
• Systemic Lupus Erythematosus (SLE)
• Suspected Antiphospholipid Syndrome

Preparation Before Test

Sample Required

• Peripheral venous blood sample (Serum)

Preparation Guidelines

• No fasting is generally required.
• Continue medications unless advised otherwise by your physician.
• Inform your healthcare provider about anticoagulant therapy, autoimmune diseases, pregnancy history, or previous blood clots.
• Follow laboratory instructions before sample collection.

Reporting Time

Results are generally available within 3–7 working days, depending on laboratory methodology.

Who Should Take This Test?

This test is recommended for:

• Individuals with suspected Antiphospholipid Syndrome (APS)
• Patients with unexplained venous or arterial thrombosis
• Women with recurrent miscarriages or pregnancy complications
• Patients with Systemic Lupus Erythematosus (SLE)
• Individuals with autoimmune disorders associated with thrombosis
• Patients referred by rheumatologists, hematologists, obstetricians, or physicians

Clinical Significance

A positive Beta 2 Glycoprotein 1 (β2GP1) IgM antibody result may indicate:

• Antiphospholipid Syndrome (APS)
• Autoimmune Thrombotic Disorder
• Increased Risk of Venous or Arterial Thrombosis
• Pregnancy-Related Complications

Common clinical features associated with APS include:

• Deep vein thrombosis (DVT)
• Pulmonary embolism
• Stroke or transient ischemic attack (TIA)
• Recurrent miscarriages
• Stillbirth
• Pre-eclampsia
• Low platelet count (thrombocytopenia)
• Livedo reticularis (mottled skin appearance)

A positive Beta 2 Glycoprotein 1 IgM result should always be interpreted together with clinical findings and other antiphospholipid antibody tests. According to international diagnostic guidelines, persistent positivity on two separate occasions at least 12 weeks apart, combined with appropriate clinical features, supports the diagnosis of Antiphospholipid Syndrome.